1. Home
  2. ZNTL vs YARW Comparison

ZNTL vs YARW Comparison

Compare ZNTL & YARW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Zentalis Pharmaceuticals Inc.

ZNTL

Zentalis Pharmaceuticals Inc.

N/A

Current Price

$1.37

Market Cap

165.1M

Sector

Health Care

ML Signal

N/A

Logo Yarrow Bioscience Inc. Common Stock

YARW

Yarrow Bioscience Inc. Common Stock

N/A

Current Price

$14.18

Market Cap

154.5M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ZNTL
YARW
Founded
2014
2021
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
165.1M
154.5M
IPO Year
2020
2017

Fundamental Metrics

Financial Performance
Metric
ZNTL
YARW
Price
$1.37
$14.18
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
11
5
Target Price
$7.44
★ $53.00
AVG Volume (30 Days)
★ 1.3M
170.3K
Earning Date
11-09-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
18.03
★ 33.33
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$1.28
$12.39
52 Week High
$6.95
$44.28

Technical Indicators

Market Signals
Indicator
ZNTL
YARW
Relative Strength Index (RSI) 22.22 37.85
Support Level N/A $12.39
Resistance Level $1.98 $20.35
Average True Range (ATR) 0.18 2.79
MACD -0.01 -0.05
Stochastic Oscillator 0.72 22.69

Price Performance

Historical Comparison
ZNTL
YARW

About ZNTL Zentalis Pharmaceuticals Inc.

Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.

About YARW Yarrow Bioscience Inc. Common Stock

Yarrow Bioscience Inc is a clinical-stage biopharmaceutical company focused on developing biotherapeutics for autoimmune thyroid diseases. Its flagship product candidate, YB-101 (also known as GenSci098), is a humanized, monoclonal antibody targeting the thyroid-stimulating hormone receptor, which Yarrow plans to develop for the treatment of Graves' disease (GD) and potentially thyroid eye disease (TED). The company has one reportable segment relating to the research and development of its research programs, GD and TED.

Share on Social Networks: